An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: a pilot study

2021 ◽  
Author(s):  
Rocío Mateo-Gallego ◽  
Isabel Moreno-Indias ◽  
Ana M. Bea ◽  
Lidia Sánchez-Alcoholado ◽  
Antonio J. Fumanal ◽  
...  

An alcohol-free beer including the substitution of regular carbohydrates for low doses of isomaltulose and maltodextrin within meals significantly impacts gut microbiota in diabetic subjects with overweight or obesity.

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Mohammad Tahseen Al Bataineh ◽  
Nihar Ranjan Dash ◽  
Pierre Bel Lassen ◽  
Bayan Hassan Banimfreg ◽  
Aml Mohamed Nada ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mohammad Tahseen Al Bataineh ◽  
Nihar Ranjan Dash ◽  
Pierre Bel Lassen ◽  
Bayan Hassan Banimfreg ◽  
Aml Mohamed Nada ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mohammad Tahseen Al Bataineh ◽  
Nihar Ranjan Dash ◽  
Pierre Bel Lassen ◽  
Bayan Hassan Banimfreg ◽  
Aml Mohamed Nada ◽  
...  

An amendment to this paper has been published and can be accessed via a link at the top of the paper.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1131-P ◽  
Author(s):  
MILOS MRAZ ◽  
IDAN MARCOVITCH ◽  
IVANA LANKOVA ◽  
HELENA KRATOCHVILOVA ◽  
ANNA CINKAJZLOVA ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 973-P
Author(s):  
ALLISON LAROCHE ◽  
KRISTINA UTZSCHNEIDER ◽  
CATHERINE PIHOKER

2021 ◽  
Vol 22 (7) ◽  
pp. 3566
Author(s):  
Chae Bin Lee ◽  
Soon Uk Chae ◽  
Seong Jun Jo ◽  
Ui Min Jerng ◽  
Soo Kyung Bae

Metformin is the first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM); however, its mechanism of modulating glucose metabolism is elusive. Recent advances have identified the gut as a potential target of metformin. As patients with metabolic disorders exhibit dysbiosis, the gut microbiome has garnered interest as a potential target for metabolic disease. Henceforth, studies have focused on unraveling the relationship of metabolic disorders with the human gut microbiome. According to various metagenome studies, gut dysbiosis is evident in T2DM patients. Besides this, alterations in the gut microbiome were also observed in the metformin-treated T2DM patients compared to the non-treated T2DM patients. Thus, several studies on rodents have suggested potential mechanisms interacting with the gut microbiome, including regulation of glucose metabolism, an increase in short-chain fatty acids, strengthening intestinal permeability against lipopolysaccharides, modulating the immune response, and interaction with bile acids. Furthermore, human studies have demonstrated evidence substantiating the hypotheses based on rodent studies. This review discusses the current knowledge of how metformin modulates T2DM with respect to the gut microbiome and discusses the prospect of harnessing this mechanism in treating T2DM.


Gut Pathogens ◽  
2021 ◽  
Vol 13 (1) ◽  
Author(s):  
A. L. Cunningham ◽  
J. W. Stephens ◽  
D. A. Harris

AbstractA strong and expanding evidence base supports the influence of gut microbiota in human metabolism. Altered glucose homeostasis is associated with altered gut microbiota, and is clearly associated with the development of type 2 diabetes mellitus (T2DM) and associated complications. Understanding the causal association between gut microbiota and metabolic risk has the potential role of identifying susceptible individuals to allow early targeted intervention.


Sign in / Sign up

Export Citation Format

Share Document